'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The ...
Telix Pharmaceuticals announces primary results from Phase III ZIRCON trial, published in The Lancet Oncology, showing TLX250-CDx (Zircaix®) is highly accurate in detecting clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs), with a favourable safety profile and potential to be practice-changing.
Related Clinical Trials
Reference News
Telix's Phase 3 ZIRCON trial results published in The Lancet Oncology show TLX250-CDx (Zircaix) is highly accurate for detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses, potentially reducing unnecessary surgeries and improving patient outcomes.
Telix Pharmaceuticals announces primary results from its Phase III ZIRCON1 trial, published in The Lancet Oncology, showing TLX250-CDx (Zircaix®) is highly accurate in detecting and characterizing clear cell renal cell carcinoma in patients with indeterminate renal masses.
Telix Pharmaceuticals announces primary results from Phase III ZIRCON trial, published in The Lancet Oncology, showing TLX250-CDx (Zircaix®) is highly accurate in detecting clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs), with a favourable safety profile and potential to be practice-changing.
The phase 3 ZIRCON trial reported TLX250-CDx's high accuracy in detecting ccRCC, with sensitivity of 85.5% and specificity of 87%. Telix must resubmit the BLA for TLX250-CDx after FDA concerns over sterility assurance. TLX250-CDx aims to be the first targeted PET agent for kidney cancer in the U.S.
Telix Pharmaceuticals announces primary results from Phase III ZIRCON trial published in The Lancet Oncology, showing TLX250-CDx (Zircaix®) highly accurate in detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs), potentially reducing unnecessary surgeries.